MORNINGSTAR INC.

- USD (-)

- 15 min delayed data - NASDAQ Stocks

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	MORN
ISIN:

MORNINGSTAR INC. overview

> Analyses

Londinia AI has published a new analysis for Vincent Launay.

0
93957
15805
0

MORNINGSTAR INC. - Daily

Timeframe : Daily - Simple chart
Status : INVALID

All elements being rather bullish, it would be possible for traders to only trade long positions (at the time of purchase) on MORNINGSTAR INC. as long as the price remains well above 155.21 USD. The…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis for Vincent Launay.

0
93957
15805
0

MORNINGSTAR INC. - Daily

Timeframe : Daily - Simple chart
Status : TARGET REACHED

MORNINGSTAR INC. is part of a very strong bullish trend. Traders may consider trading only long positions (at the time of purchase) as long as the price remains well above 148.32 USD. The next…

Thank you Reply Chart

> News ACCESSWIRE published a news.

MorphoSys AG Reports First Quarter 2018 Results • • ACCESSWIRE • Stocks • More MORNINGSTAR INC. news...

Conference call and webcast (in English) to be held on May 3, 2018, at 2:00pm CEST (1:00pm BST/8:00am EDT) - Successful capital increase and U.S. Nasdaq listing closed in April 2018 with total gross proceeds of USD 239.0 million - MOR208: Updated data in DLBCL presented, constructive discussions with FDA regarding path to market for MOR208 under current breakthrough therapy designation ongoing - Tremfya (R) : Partner Janssen received approvals in Japan, Brazil, Australia and South Korea -...

Thank you Chart

> News ACCESSWIRE published a news.

MorphoSys and Galapagos Announce Initiation of the IGUANA Phase 2 Clinical Trial with MOR106 in Atopic Dermatitis Patients • • ACCESSWIRE • Stocks • More MORNINGSTAR INC. news...

PLANEGG and MUNICH, GERMANY and MECHELEN, BELGIUM / ACCESSWIRE / May 1, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR; OTC: MPSYY) and Galapagos NV (GLPG) announced today that the first patient has been enrolled in IGUANA, a phase 2 study with MOR106, an investigational antibody directed against IL-17C, in atopic dermatitis patients. IGUANA - A MOR106 phase 2 trial At least 180 patients with moderate-to-severe atopic dermatitis (AD) are planned be treated over a...

Thank you Chart

Load more content